Pharma / Biotech

Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective.


Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective.

Drug Discov Today. 2020 Jul 18;:

Authors: Pike A, Williamson B, Harlfinger S, Martin S, McGinnity DF

Abstract
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality with the potential to open target space not accessible to conventional small molecules via a degradation-based mechanism; however, their bifunctional nature can result in physicochemical properties that breach commonly accepted limits for small-molecule oral drugs. We offer a drug metabolism and pharmacokinetics (DMPK) perspective on the optimisation of oral PROTACs across a diverse set of projects within Oncology R&D at AstraZeneca, highlighting some of the challenges that they have presented to our established screening cascade. Furthermore, we challenge some of the perceptions and dogma surrounding the feasibility of oral PROTACS and demonstrate that acceptable oral PK properties for this modality can be regularly achievable despite the physicochemical property challenges they present.

PMID: 32693163 [PubMed – as supplied by publisher]

Source link

Related posts

SEVERE SINUS CONGESTION RELIEF (acetaminophen, dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride) capsule, liquid filled [Chain Drug Marketing Association Inc.]

Newsemia

AMPICILLIN (Ampicillin Sodium) Injection, Powder, For Solution [Fresenius Kabi USA, LLC]

Newsemia

Getting to the Heart of Untreated Depression

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World